Prevention of venous thromboembolism in hospitalized patients with cancer.
This is a literature review of the frequency of venous thromboembolism in hospitalized patients with cancer and of the available evidence supporting the use of thromboprophylaxis. Patients with cancer are at particularly high risk of venous thromboembolism and account for almost 20% of patients in the population. Hospitalization is an important risk factor in patients with cancer, with rates reported between 0.6% and 7.8%. The incidence has been increasing over the past decade. Three randomized controlled trials and meta-analyses indicate that prophylaxis with low molecular weight heparin, heparin, or fondaparinux significantly reduces the rate of venous thromboembolism in hospitalized medical patients who are at high risk. Patients with cancer were included in these studies, but prospective trials specifically focused on patients with cancer are not available. Evidence indicates that appropriate thromboprophylaxis is provided to a minority of hospitalized patients with cancer and that targeted educational efforts and computerized prompt systems can increase appropriate use. Guidelines developed by both oncology and thrombosis organizations support the use of thromboprophylaxis in hospitalized patients with cancer. In conclusion, most patients hospitalized with cancer are at high risk of venous thromboembolism, and thromboprophylaxis should be provided in the absence of active bleeding or a high bleeding risk.
Francis
Charles W
CW
Department of Medicine, University of Rochester, Rochester, NY, USA. charles_francis@urmc.rochester.edu
D000925:Anticoagulants / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D005500:Follow-Up Studies; D017052:Hospital Mortality / Q000639:trends*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D010690:Phlebography; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods / Q000592:standards*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants
Arch Intern Med. 2002 Jun 10;162(11):1245-8
12038942
Lancet. 1975 Jul 12;2(7924):45-51
49649
Thromb Res. 2007;119(2):145-55
16516275
Arch Intern Med. 2004 May 10;164(9):963-8
15136304
Chest. 2008 Jun;133(6 Suppl):454S-545S
18574272
Thromb Haemost. 2007 Sep;98(3):656-61
17849056
Blood. 2002 Nov 15;100(10):3484-8
12393647
Ann Intern Med. 2007 Feb 20;146(4):278-88
17310052
Chest. 2008 Jun;133(6 Suppl):381S-453S
18574271
Br J Surg. 1999 Aug;86(8):992-1004
10460633
J Clin Oncol. 2007 Dec 1;25(34):5490-505
17968019
Cochrane Database Syst Rev. 2000;(3):CD001484
10908501
BMJ. 1994 Jan 22;308(6923):235-46
8054013
Chest. 1995 Oct;108(4):978-81
7555172
Arch Intern Med. 2004 Aug 9-23;164(15):1653-61
15302635
Chest. 2004 Sep;126(3 Suppl):338S-400S
15383478
J Clin Pathol. 1997 Jul;50(7):609-10
9306945
Arch Intern Med. 1998 Mar 23;158(6):585-93
9521222
BMJ. 2006 Feb 11;332(7537):325-9
16439370
Ann Intern Med. 1991 Oct 15;115(8):591-5
1892330
Evid Rep Technol Assess (Summ). 2001;(43):i-x, 1-668
11510252
Chest. 1994 Jul;106(1):13-4
8020258
Haematologica. 2002 Jul;87(7):746-50; discussion 250
12091126
N Engl J Med. 1999 Sep 9;341(11):793-800
10477777
Medicine (Baltimore). 1999 Sep;78(5):285-91
10499070
Thromb Haemost. 2000 Jan;83(1):14-9
10669147
Arch Intern Med. 2000 Mar 27;160(6):809-15
10737280
Cancer. 2007 Nov 15;110(10):2339-46
17918266
Oncologist. 2003;8(4):381-8
12897335
N Engl J Med. 2001 Sep 27;345(13):965-70
11575289
Value Health. 2003 Jan-Feb;6(1):59-74
12535239
Am J Cardiol. 2004 Jan 15;93(2):259-62
14715365
N Engl J Med. 2005 Mar 10;352(10):969-77
15758007
Thromb Haemost. 2002 Apr;87(4):575-9
12008937
Circulation. 2004 Aug 17;110(7):874-9
15289368
J R Soc Med. 1989 Apr;82(4):203-5
2716016
J Clin Oncol. 2006 Jan 20;24(3):484-90
16421425
Arch Intern Med. 1994 Mar 28;154(6):669-77
8129501
Circulation. 2004 Dec 14;110(24 Suppl 1):IV25-32
15598645
Br J Surg. 1991 Jul;78(7):849-52
1873716
Arch Intern Med. 2008 Nov 24;168(21):2377-81
19029504
BMJ. 2003 Sep 13;327(7415):597-8
12969928
Arch Intern Med. 1991 May;151(5):933-8
2025141
N Engl J Med. 1988 May 5;318(18):1162-73
3283548
Am J Med. 2006 Jan;119(1):60-8
16431186
Chest. 2000 Dec;118(6):1680-4
11115458